Semaglutide is an FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes and weight management; this page summarizes its label and research context for educational use only, not medical advice.
Standard Access: This compound's three paid filesAll-Access Lifetime: all 55 guides + every printableEducational content only
Semaglutide Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Semaglutide at a glance
What it is
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, approved as Ozempic, Wegovy and Rybelsus
Researched for
Type 2 diabetes, chronic weight management, and cardiovascular risk reduction
Plasma half-life
Approximately 1 week (elimination half-life about 155 hours)
Regulatory status
FDA-approved and prescription-only. Research-market material is NOT the pharmacy product and is research use only
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
Semaglutide is an acylated analog of human GLP-1, an incretin hormone released from intestinal L-cells after eating. Substitutions at positions 8 and 34 make it resistant to degradation by dipeptidyl peptidase-4, and a C18 fatty-diacid chain attached via a linker promotes reversible albumin binding; together these give it a duration of action long enough for weekly dosing. At the GLP-1 receptor it is reported to enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, and slow gastric emptying. Because the insulin effect is glucose-dependent, the risk of hypoglycaemia from the drug alone is described as low, though it rises when combined with insulin or sulfonylureas. Receptors in hypothalamic and hindbrain appetite circuits are the reported basis of the reduction in appetite and energy intake that drives weight loss.
Researched effects
In clinical trials semaglutide has been associated with reduced HbA1c in type 2 diabetes, reduced appetite and energy intake, and substantial body-weight reduction - the STEP programme reported roughly 15% mean weight reduction at 68 weeks at the 2.4 mg dose in people with obesity, and the SELECT trial reported a reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity. These are reported trial findings in supervised populations, not guaranteed outcomes; individual results varied considerably, and weight regain after discontinuation has been reported. Nothing here is a promise of efficacy or a personal recommendation.
Evidence & regulatory status
Evidence base: a large Phase 3 programme (SUSTAIN in type 2 diabetes, STEP in weight management, SELECT in cardiovascular outcomes) plus extensive pharmacokinetic characterization. This is one of the most thoroughly studied peptides in the catalog.
Regulatory status: FDA-approved and prescription-only - Ozempic (2017, type 2 diabetes), Rybelsus (2019, oral), Wegovy (2021, chronic weight management). Approved products are supplied through pharmacies with a prescription and clinician supervision.
Research-use framing: material sold on the research market as semaglutide is NOT the approved pharmacy product, is not manufactured to pharmaceutical standards, and is supplied for laboratory research only. Dosing described here reflects the approved label and published trials for educational context, not clinical guidance.
Research timeline
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
First registered human study begins: single ascending doses in 58 healthy men in Europe, under the development code NNC 0113-0217. The record was registered retrospectively, in 2017. NCT03144271
Novo Nordisk's chemists publish how semaglutide was designed: two amino-acid substitutions against human GLP-1 (Aib8, Arg34) and a fatty-acid chain on lysine 26 that raises albumin binding, chosen as the once-weekly candidate. PMID 26308095
The phase 2 dose-finding trial is published: 415 adults with type 2 diabetes over 12 weeks. HbA1c and body weight fell more as the dose rose, and so did nausea, vomiting and withdrawals for gastrointestinal effects. PMID 26358288
SUSTAIN 6 is published: in 3,297 adults with type 2 diabetes, cardiovascular death, heart attack or stroke occurred in 6.6% on semaglutide versus 8.9% on placebo over two years. Retinopathy complications were more frequent on semaglutide. PMID 27633186
FDA approves Ozempic (semaglutide injection) for type 2 diabetes in adults. FDA · NDA 209637
FDA approves Rybelsus, semaglutide as a tablet taken by mouth, for type 2 diabetes in adults. FDA · NDA 213051
FDA adds a cardiovascular indication to Ozempic on the strength of SUSTAIN 6: reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. FDA · NDA 209637/S-003
STEP 1 is published: 1,961 adults with obesity or overweight and no diabetes lost 14.9% of body weight on average over 68 weeks on semaglutide, against 2.4% on placebo. PMID 33567185
FDA approves Wegovy (semaglutide injection) for chronic weight management in adults. FDA · NDA 215256
FDA extends Wegovy to adolescents aged 12 and older with obesity, based on the STEP TEENS trial. FDA · NDA 215256/S-005
SELECT is published: in 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes, cardiovascular death, heart attack or stroke occurred in 6.5% on semaglutide versus 8.0% on placebo. Adverse events ended treatment for 16.6% versus 8.2%. PMID 37952131
FDA adds a cardiovascular indication to Wegovy based on SELECT: reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. FDA · NDA 215256/S-011
FLOW is published: in 3,533 adults with type 2 diabetes and chronic kidney disease, kidney failure, a fall in kidney function of at least half, or death from kidney or cardiovascular causes was 24% less frequent on semaglutide than placebo. The trial stopped early at a planned interim analysis. PMID 38785209
FDA adds a kidney indication to Ozempic: reducing the risk of sustained kidney-function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. FDA · NDA 209637/S-025
SOUL is published: in 9,650 adults with type 2 diabetes and cardiovascular or kidney disease, major cardiovascular events occurred in 12.0% on oral semaglutide versus 13.8% on placebo over a median of about four years. PMID 40162642
ESSENCE interim results are published: in 800 adults with biopsy-confirmed MASH and moderate or advanced fibrosis, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide versus 34.3% on placebo at 72 weeks. PMID 40305708
FDA grants Wegovy accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis in adults; the approval depends on a confirmatory trial. FDA · NDA 215256/S-024
OASIS 4 is published: 307 adults with obesity or overweight and no diabetes lost 13.6% of body weight on average at 64 weeks on oral semaglutide, against 2.2% on placebo; gastrointestinal adverse events affected 74.0% versus 42.2%. PMID 40934115
FDA adds a cardiovascular indication to Rybelsus: reducing major cardiovascular events in adults with type 2 diabetes at high risk of them. FDA · NDA 213051/S-024
FDA approves Wegovy tablets, a form of semaglutide taken by mouth, under a new application. FDA · NDA 218316
Records checked Oct 3, 2026
Claims at a glance
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
Produces about 15% weight lossHuman, randomised trial. STEP 1, 1,961 adults with obesity or overweight: −14.9% at 68 weeks against −2.4% on placebo; about half reached 15%. PMID 33567185
The weight comes back after stoppingHuman, randomised trial. STEP 4 randomised 803 people after a 20-week lead-in: those switched to placebo regained 6.9% while those who continued lost a further 7.9%. PMID 33755728
Cuts heart attacks and strokesHuman, randomised trial. SELECT, 17,604 people with established cardiovascular disease and obesity but no diabetes: major cardiovascular events in 6.5% against 8.0% on placebo. PMID 37952131
Protects the kidneysHuman, randomised trial. FLOW, 3,533 people with type 2 diabetes and kidney disease: 24% lower risk of the kidney-failure composite; shown in that population only. PMID 38785209
Improves fatty liver disease (MASH)Human, randomised trial. ESSENCE interim analysis, 800 patients with biopsy-proven disease: steatohepatitis resolved in 62.9% against 34.3% on placebo at week 72. PMID 40305708
Slows Alzheimer's diseaseHuman, randomised trial. Not supported: two phase 3 trials, 3,808 people with early Alzheimer's, found no difference from placebo over two years. PMID 41865758
Spares muscle while burning fatHuman, randomised trial. In a randomised body-scan substudy, lean mass fell along with fat; its share of body weight rose slightly, much as with the comparator drug. PMID 31897524
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 5, 2026
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Half-life & pharmacokinetics
Semaglutide has an elimination half-life of approximately 155 hours, or about one week, which is the basis for once-weekly dosing. Steady state is reached after roughly 4 to 5 weeks of consistent weekly administration, which is also why the label escalates at 4-week intervals - each step is assessed near steady state rather than mid-accumulation. The long half-life means the drug persists for several weeks after the last dose.
Reported side effects & toxicology
The most commonly reported adverse effects are gastrointestinal - nausea, vomiting, diarrhoea, constipation and abdominal pain - which are dose-related and most frequent during escalation. The label carries a boxed warning for thyroid C-cell tumours based on rodent studies, and the label lists a personal or family history of medullary thyroid carcinoma or MEN 2 as a contraindication. Pancreatitis, gallbladder disease, acute kidney injury secondary to dehydration, and diabetic retinopathy complications have been reported, and hypoglycaemia risk rises when combined with insulin or sulfonylureas. Loss of lean mass alongside fat mass has also been discussed. This is a summary of reported label safety information, not an exhaustive profile, and nothing here is medical advice - these risks are among the reasons this is a supervised prescription medicine.
Storage & handling
Approved pre-filled pens are stored refrigerated at 2-8 C before first use and protected from light; consult the product label for in-use storage, which differs by product.
Research-market lyophilized vials are typically stored refrigerated and protected from light; after reconstitution keep refrigerated at about 2-8 C, use within a few weeks, do not freeze and avoid shaking.
References
Primary sources include the FDA prescribing information for Wegovy, Ozempic and Rybelsus (dose escalation, half-life, warnings and contraindications) and the published Phase 3 programmes: SUSTAIN in type 2 diabetes, STEP in weight management, and the SELECT cardiovascular outcomes trial reported in the New England Journal of Medicine. Label details cited here reflect the FDA-approved labeling; readers should consult the current label, since approved indications and dosing are periodically updated.
Evidence File
The Semaglutide Evidence File: 773 Registry Records, Seven Programme Codes, and the Trial the Market Has Not Caught Up With
Semaglutide is one of the most heavily trialled molecules in this catalog, which changes what an evidence file is for: not finding data, but auditing it. This file works from a complete ClinicalTrials.gov census pulled on the verification date, from the sponsor's own internal programme codes, and from the abstracts of the trials that produced the figures the market repeats. It reads the parts of the record that summaries skip - the terminated and withdrawn tail, the studies registered under codes no chemical registry lists, the large randomised result that did not go the way the field expected - and traces each circulating number back to the analysis that produced it.
773 registry records reviewed in a single census pull
7 Novo programme codes; only 2 appear in chemical registries
9 terminated, 14 withdrawn and 1 suspended record read line by line
5 circulating figures traced to the analysis that produced them
Seven programme codes, and why searching one name misses two whole programmes
The census: 773 records, and two thirds of them are not the sponsor's
EVOKE and EVOKE Plus: the programme's one large clinical failure
Nine terminated records - and the two largest were not about semaglutide at all
Fourteen withdrawn and one suspended: the questions that were never asked
Five circulating figures, traced to the analyses that produced them
The retinopathy question is a decade old and still unanswered
A successor pipeline, and the five ways trial protocol differs from research-market practice
8 more sections in the Evidence File for Semaglutide
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Semaglutide for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
The Semaglutide Sourcing File: Two Mass Fields One Dalton Apart, a Salt the FDA Calls a Different Drug, and Three Vials That Were 99 Percent Pure on Paper
Semaglutide is unusual on the research market: an approved pharmaceutical with a complete public chemical record, sold in a form the approved product never takes. That combination creates sourcing questions no generic peptide guide covers. This file anchors the compound to its authoritative chemical record, works out from that record what a genuine mass spectrum must look like and why one widely quoted mass field means something different from what certificates claim it means, computes net peptide content for each plausible counter-ion, maps the mislabelling modes a regulator has documented for this exact molecule, audits a specimen certificate line by line against its own numbers, and closes on the one published study in which someone bought this material without a prescription and put it through an analytical laboratory.
2 PubChem mass fields 1 Da apart that mean different things
6 mislabelling modes documented by FDA for this exact compound
Net peptide computed for acetate, TFA and sodium counter-ion loads
3 test-purchased vials: 99 percent claimed on the label, far less found
Identity numbers, and the mass field certificates quote wrong more often than any other
Salt forms: what the regulator says, and what the arithmetic actually shows
What a semaglutide certificate must show, and what each line is actually for
A specimen certificate, line by line
Mislabelling and adulteration modes documented for this exact compound
The reconstitution error is documented, hospitalising and asymmetric
Laboratory comparisons of non-originator material, and who paid for them
Three vials bought without a prescription, and what an independent laboratory found in them
8 more sections in the Sourcing File for Semaglutide
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Semaglutide for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
Semaglutide Benefit and Outcome Review: Twelve Claims Graded Against What Was Actually Measured, In Whom, and For How Long
Unusually for anything in a peptide catalog, semaglutide's claims can be graded against randomised, placebo-controlled, event-driven trials with tens of thousands of participants. That changes the shape of an honest review: the verdicts here are mostly not unproven but proven in this population, at this dose, for this duration, by this margin. The value is in the qualifiers. Each claim below is set against the trial that tested it, the comparator arm's own result, the proportion who did not respond, and the population that was enrolled - plus the questions that have no answer yet, including one completed trial whose only public result sits in a registry field rather than in any journal.
12 marketed claims graded against the trials that tested them
1 claim tested at scale in 3808 people and not supported
Placebo-arm results attached to every effect size quoted
1 completed trial whose result exists only in the registry
Weight: one number, five populations, and the half who did not reach it
Stopping: two randomised looks at what happens afterwards
Cardiovascular: three trials, three populations, three different answers
Kidney: supported at one dose in one population, and null in another
Liver, heart failure, walking and knee pain: four smaller claims and their comparator arms
Cognition: the claim the largest trial tested, and did not support
Muscle: both directions are marketed, and neither is what was measured
What is still unanswered, the animal evidence, and the shape of tolerability over time
8 more sections in the Benefit & Outcome Review for Semaglutide
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Semaglutide for $14 — or every compound in the library, plus the printable reference sheets, for $99.
Quick answers about guide scope, access, and educational use context.
What is semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist approved by the FDA as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. It enhances glucose-dependent insulin release, suppresses glucagon, slows gastric emptying and reduces appetite. It is a prescription medicine.
What is the semaglutide dose escalation schedule?
The Wegovy label escalates every 4 weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then a 2.4 mg once-weekly maintenance dose, with 1.7 mg also accepted as maintenance. The gradual increase exists to limit dose-related gastrointestinal side effects. This is what the label specifies for supervised prescription use, not a recommendation for any individual.
Is research-market semaglutide the same as Ozempic or Wegovy?
No. Approved products are pharmaceutical-grade, supplied in pre-filled pens through pharmacies with a prescription and clinician oversight. Material sold on the research market is not the approved product, is not manufactured or verified to pharmaceutical standards, and is supplied for laboratory research only. They are not interchangeable.
Does this page tell me how much semaglutide to take?
No. The figures shown describe the approved label and published trials for educational context. This page does not recommend a personal dose, route or frequency and is not medical advice. Semaglutide is a prescription medicine with a boxed warning and real contraindications - any actual use should be directed and monitored by a qualified professional.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was Semaglutide. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Specific to Semaglutide
Semaglutide also exists as an approved prescription medicine. A certificate for research-market material speaks only to that batch's analysis; it does not establish equivalence to the pharmacy product, which carries manufacturing, formulation and regulatory controls no third-party assay evaluates.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
The diluent for reconstituting Semaglutide
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, produced in an FDA-registered U.S. facility and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
